Population pharmacokinetics of valproic acid in children with epilepsy: Implications for dose tailoring when switching from oral syrup to sustained‐release tablets
Open Access
- 24 June 2024
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (9) , 1554-1569
Abstract
Significant pharmacokinetic (PK) differences exist between different forms of valproic acid (VPA), such as syrup and sustained‐release (SR) tablets. This study aimed to develop a population pharmacokinetic (PopPK) model for VPA in children with epilepsy and offer dose adjustment recommendation for switching dosage forms as needed. The study collected 1411 VPA steady‐state trough concentrations (Ctrough) from 617 children with epilepsy. Using NONMEM software, a PopPK model was developed, employing a stepwise approach to identify possible variables such as demographic information and concomitant medications. The final model underwent internal and external evaluation via graphical and statistical methods. Moreover, Monte Carlo simulations were used to generate a dose tailoring strategy for typical patients weighting 20–50 kg. As a result, the PK characteristics of VPA were described using a one‐compartment model with first‐order absorption. The absorption rate constant (ka) was set at 2.64 and 0.46 h−1 for syrup and SR tablets. Body weight and sex were identified as significant factors affecting VPA's pharmacokinetics. The final PopPK model demonstrated acceptable prediction performance and stability during internal and external evaluation. For children taking syrup, a daily dose of 25 mg/kg resulted in the highest probability of achieving the desired target Ctrough, while a dose of 20 mg/kg/day was appropriate for those taking SR tablets. In conclusion, we established a PopPK model for VPA in children with epilepsy to tailor VPA dosage when switching between syrup and SR tablets, aiming to improve plasma VPA concentrations fluctuations.Keywords
This publication has 47 references indexed in Scilit:
- Reference serum creatinine levels according to sex, age, and height in children with Down syndromeEuropean Journal of Pediatrics, 2021
- Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding modelEuropean Journal of Clinical Pharmacology, 2021
- Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic modelEuropean Journal of Clinical Pharmacology, 2018
- A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsyEuropean Journal of Clinical Pharmacology, 2018
- Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid—a large-scale study based on naturalistic therapeutic drug monitoring dataEuropean Journal of Clinical Pharmacology, 2016
- Update on Estimation of Kidney Function in Diabetic Kidney DiseaseCurrent Diabetes Reports, 2015
- A Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding SaturationClinical Pharmacokinetics, 2014
- Population pharmacokinetics of valproate in Mexican children with epilepsyBiopharmaceutics & Drug Disposition, 2008
- Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokineticsEuropean Journal of Clinical Pharmacology, 2006
- Inherent Correlation Between Dose and Clearance in Therapeutic Drug Monitoring Settings: Possible Misinterpretation in Population Pharmacokinetic AnalysesJournal of Pharmacokinetics and Pharmacodynamics, 2005